Homoarginine and cardiovascular outcome in the population-based dallas heart study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 11, 2014, Pages 2501-2507

  Atzler, Dorothee ^a,c   Gore, M Odette ^d   Ayers, Colby R ^e   Choe, Chi Un ^b   Böger, Rainer H ^a,c   De Lemos, James A ^d   McGuire, Darren K ^d,e   Schwedhelm, Edzard ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d Department of Medicine   (Germany)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Epidemiology; Nitric oxide

Indexed keywords

CALCIUM; GLYCINE AMIDINOTRANSFERASE; HOMOARGININE; BIOLOGICAL MARKER;

ADULT; AMINO ACID BLOOD LEVEL; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY CALCIUM SCORE; DISEASE ASSOCIATION; ELECTRON BEAM TOMOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; AORTA; BLOOD; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDY; ECHOGRAPHY; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; UNITED STATES;

ADULT; AORTA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HOMOARGININE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TEXAS;

EID: 84911869613     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304398     Document Type: Article

References (29)

1. Bretscher LE, Li H, Poulos TL, Griffith OW. Structural characterization and kinetics of nitric-oxide synthase inhibition by novel N5-(imi noalkyl)-and N5-(iminoalkenyl)-ornithines. J Biol Chem. 2003;278:46789-46797.
2. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-5197.
3. Thomas G, Myers A, Farhat M, Cathapermal S, Ramwell PW. Effect of N-substituted arginine compounds on blood pressure in anesthetized rats. J Pharmacol Exp Ther. 1992;261:875-878.
4. Mä rz W, Meinitzer A, Drechsler C, Pilz S, Krane V, Kleber ME, Fischer J, Winkelmann BR, Bö hm BO, Ritz E, Wanner C. Homoarginine, cardiovascular risk, and mortality. Circulation. 2010;122:967-975.
5. Pilz S, Meinitzer A, Tomaschitz A, Drechsler C, Ritz E, Krane V, Wanner C, Boehm BO, Mä rz W. Low homoarginine concentration is a novel risk factor for heart disease. Heart. 2011;97:1222-1227.
6. Pilz S, Tomaschitz A, Meinitzer A, Drechsler C, Ritz E, Krane V, Wanner C, Böhm BO, Mä rz W. Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography. Stroke. 2011;42:1132-1134.
7. Böger RH, Sulli van LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation . 2009;119:1592-1600.
8. Kragelund C, Grø nning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N En gl J Med. 2005;352:666-675.
9. Atzler D, Rosenberg M, Anderssohn M, Choe CU, Lutz M, Zugck C, Böger RH, Frey N, Schwedhelm E. Homoarginine-an independent marker of mortality in hea rt failure. Int J Cardiol. 2013;168:4907-4909.
10. Choe CU, Atzler D, Wild PS, et al. Homoarginine levels are regulated by L-arginine:glycine amidinotransferase and affect stroke outcome: result s from human and murine studies. Circulation. 2013;128:1451-1461.
11. Drechsler C,Meinitzer A,Pilz S,Krane V,Tomaschitz A,Ritz E,März W,Wanner C. Homoarginine, heart failu re, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail. 2011;13:852-859.
12. Tomaschitz A, Meinitzer A, Pilz S, Rus-Machan J, Genser B, Drechsler C, Grammer T, Krane V, Ritz E, Kleber ME, Pieske B, Kraigher-Krainer E, Fahrleitner-Pammer A, Wanner C, Boehm BO, Mä rz W. Homoarginine, kidney function and cardiovascular mortality risk. Nephrol Dial Transplant. 2014;44:200-208
13. Pilz S, Meinitzer A, Tomaschitz A, Kienreich K, Dobnig H, Schwarz M, Wagner D, Drechsler C, Piswanger-Sölkner C, Mä rz W, Fahrleitner-Pammer A. Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients. Osteoporos Int. 2013;24:377-381.
14. Pilz S, Meinitzer A, Toma schitz A, Kienreich K, Fahrleitner-Pammer A, Drechsler C, Boehm BO, Mä rz W. Homoarginine deficiency is associated with increased bone turnover. Osteoporos Int. 2012;23:2731-2732.
15. Bög er RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38:126-136.
16. Gore MO, Lü neburg N, Schwedhelm E, Ayers CR, Anderssohn M, Khera A, Atzler D, de Lemos JA, Grant PJ, McGuire DK, Bö ger RH. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study. Arterioscler Thromb Vasc Biol. 2013;33:2682-2688.
17. Kleber ME, Seppä lä I, Pilz S, et al. Genome-wide association study identifies 3 genomic loci significantly associated with ser um levels of homoarginine: the AtheroRemo Consortium. Circ Cardiovasc Genet. 2013;6:505-513.
18. Michel T. R is for arginine: metabolism of arginine takes off again, in new directions. Circulation. 2013;128:1400-1404.
19. Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D. Substrate specificity of NO synthases: detailed comparison of L-arginine, homo-L-arginine, their N omega-hydroxy derivative s, and N omega-hydroxynor-L-arginine. Biochemistry. 1998;37:10453-10460.
20. Hrabá k A, Bajor T, Temesi A. Comparison of substrate and inhibitor specificity of arginase and nitric oxide (NO) synthase for arginine analogues and related compounds in murine and rat macrophages. Biochem Biophys Res Commun. 1994;198:206-212.
21. Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, Berry JD, McGuire DK, de Lemos JA. Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. Arterioscler Thr omb Vasc Biol. 2009;29:1684-1690.
22. Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA. Relation of coronary atherosclerosis det ermined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol. 2005;96:1284-1289.
23. C hen LQ, Rohatgi A, Ayers CR, Das SR, Khera A, Berry JD, McGuire DK, de Lemos JA. Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study. Atherosclerosis . 2011;219:833-838.
24. Choe CU, Nabuurs C, Stockebrand MC, Neu A, Nunes P, Morellini F, Sauter K, Schillemeit S, Hermans-Borgmeyer I, Marescau B, Heerschap A, Isbrandt D. L-arginine:glycine amidinotransferase deficiency protects from metabolic syndrome. Hum Mol Genet. 2013;22:110-123.
25. Davids M, Ndika JD, Salomons GS, Blom HJ, Teerlink T. Promiscuous a ctivity of arginine:glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine. FEBS Lett. 2012;586:3653-3657.
26. Drechsler C, Kollerits B, Meinitze r A, März W, Ritz E, Kö nig P, Neyer U, Pilz S, Wanner C, Kronenberg F; MMKD Study Group. Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study. PLoS One. 2013;8:e63560.
27. Pilz S, Teerlink T, Scheffer PG, Meinitzer A, Rutters F, Tomaschitz A, Drechsler C, Kienreich K, Nijpels G, Stehouwer CD, Marz W, Dekker JM. Homoargini ne and mortality in an older population: The hoorn study. Eur J Clin Invest. 2014;44:200-208.
28. Ravani P, Maas R, Malberti F, Pecchini P, Mieth M, Quinn R, Tripepi G, Mallamaci F, Zoccali C. Homoarginine and mortality in predialysis chronic kidney disease (CKD) patients. PLoS One. 2013;8: e72694.
29. van der Zwan LP, Davids M, Scheffer PG, Dekker JM, Stehouwer CD, Teerlink T. L-Homoarginine and L-arginine are antagonis tically related to blood pressure in an elderly population: the Hoorn study. J Hypertens. 2013;31:1114-1123.